NEW
Font size
WorksheetsOzempic® novoCare Multan Team Training (27 Sep 2021)
Total questions: 25
Worksheet time: 13mins
Glucose dependant secretion of insulin in response to nutrient intake is called
GLP1
Incretin effect
GIP
All of above
GLP1 mediates it’s effects via receptors belonging to.........these receptors are found in pancreatic islets and also various other tissues throughout the body including brain, kidney, liver
GLP Protein-coupled receptor family
GIP Protein-coupled receptor family
G Protein-coupled receptor family
Both A & B
Incretin based therapies include
DPP4 & GLP1
Only GLP1 RA
Wish I knew!
Semaglutide is a .....................GLP1 with ................. homology To native GLP1 hormone
Human GLP-1 analogue, 94%
GLP-1 Receptor agonist, 94%
Human GLP-1 analogue, 97%
Both A & B are correct
GLP1 stands for
Good laboratory practice
Glucagon like peptide
Guaranteed low price
Glycogen like peptide
An optimal diabetes therapy would provide improved glycemic control with minimal risk of hypoglycaemia, improve beta cell function & target other associated pathological defects of T2DM such as ........... , ............ & ..............
Depression, Anxiety & Psychosis
Obesity, Hypertension & Dyslipidaemia
Osteoporosis, Cancer & Appendicitis
I don’t know
GLP1 is a natural incretin hormone secreted by ................ in response to food intake
Stomach
Pancreas
Kidneys
Intestine
GLP1 stimulates insulin secretion & suppresses glucagon secretion but only when glucose levels are elevated thus protecting against hypoglycaemia
True
False
I don’t know
GLP1 delays stomach emptying and reduces appetite resulting in satiety (feeling of fullness) and contributing to weight loss
True
False
I don’t know
Native GLP1 has limited potential as a treatment for type 2 diabetes as it is rapidly degraded by enzyme ............ resulting in a half life of approx...............
DNA polymerase, 3 min
DNA polymerase, 1.5 minS
DPP-4, 3 mins
DPP-4, 1.5 mins
GLP1 based therapies with .......... have been developed to clinically benefit from the positive effects of GLP1 receptor activation
Short half life
Long half life
I don’t know
Multiple physiological effects of GLP1 RA, makes it an attractive Type 2 Diabetes therapy.
Agreed
Disagreed
I don’t care
Strongly Agreed
ADA/EASD guidelines recommends GLP1 RA as the ...................... injectable after metformin & before initiating ......................
Second, Insulins
Second, DPP4i
First, Insulins
First, DPP4
GLP1 RAs reduce cardiovascular risk by modifying progression of atherosclerosis (the build up of fatty deposits in the arteries)
True
False
I don’t care (Neutral)
GLP1 RAs are recommended by guidelines in ................. patients with ASCVD (Atherosclerotic cardiovascular disease)
Overweight
Type 1 diabetic
Type 2 diabetic
All of above
Modifications to native GLP1 molecule makes Semaglutide increases its albumin affinity and stability against metabolic degradation by DPP-4 giving it a half life of Approx............... making it suitable for ..................administration
7 days, Once weekly
5 days, Once weekly
13 hours, Once weekly
9 hours, Twice daily
Ozempic (Semaglutide) is administered subcutaneously (abdomen, thigh or upper arm), once weekly (OW) on the same day each week, at any time of the day with or without meals
True
False
Ozempic (Semaglutide) will be available in Pakistan as:
Two Pre-Filled pens (DUAL Pen & 1 mg pen)
Three Pre-Filled pens (0.25 mg, 0.5 mg & 1mg)
Wish I knew!
Ozempic (Semaglutide) is the most effective once weekly GLP-1 RA treatment for Type 2 Diabetes
Absolutely
Hope so
Will find out
Wish I Knew!
No significant drug–drug interactions were observed when semaglutide was administered concomitantly with oral contraceptives, metformin, warfarin, atorvastatin and digoxin?
TRUE
FALSE
What are the effects of semaglutide on appetite, energy intake and weight loss?
Lowered energy intake and energy expenditure
Corresponding reduction in body weight
loss of appetite & food cravings
ALL of the above
Semaglutide exposure was not affected by hepatic or renal impairment in patients with T2D; therefore, it may be suitable for such patients without the need for dose adjustment.
TRUE
FALSE
The SUSTAIN programme covers all aspects of the T2D patient care continuum, including ----- ---?
Drug naive patients
On OAD therapies at baseline
With basal insulin
All of above
Does semaglutide pass the blood–brain barrier?
TRUE
FALSE
Semaglutide worsened several aspects of beta-cell function vs placebo in subjects with T2D after 12 weeks of treatment. TRUE OR FALSE
TRUE
FALSE
